French national diagnostic and care protocol for Sjögren's syndrome.

[1]  R. Moots,et al.  Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial , 2021, The Lancet.

[2]  E. Andrès,et al.  Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial , 2020, Annals of the Rheumatic Diseases.

[3]  T. Sumida,et al.  Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial , 2020, Annals of the Rheumatic Diseases.

[4]  Augustine S. Lee,et al.  Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s , 2020, Chest.

[5]  A. Vissink,et al.  Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. , 2020, Clinical and experimental rheumatology.

[6]  M. Kreuter,et al.  Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. , 2020, The Lancet. Respiratory medicine.

[7]  M. Kramer,et al.  Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. , 2020, The Lancet. Respiratory medicine.

[8]  Mimi Y. Kim,et al.  Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. , 2020, Journal of the American College of Cardiology.

[9]  X. Mariette,et al.  Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone , 2020, Annals of the Rheumatic Diseases.

[10]  A. Vissink,et al.  Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study) , 2020 .

[11]  R. Jonsson,et al.  Primary Sjögren's syndrome and the eye. , 2020, Survey of ophthalmology.

[12]  S. Cerri,et al.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review , 2020, Journal of clinical medicine.

[13]  D. Isenberg,et al.  Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. , 2020, The Lancet. Rheumatology.

[14]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Fischer-Betz,et al.  Routine repeated echocardiographic monitoring of fetuses exposed to maternal anti-SSA antibodies: time to question the dogma. , 2019, The Lancet. Rheumatology.

[16]  X. Mariette,et al.  EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies , 2019, Annals of the rheumatic diseases.

[17]  X. Mariette,et al.  Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. , 2019, Rheumatology.

[18]  X. Mariette,et al.  Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome , 2019, RMD Open.

[19]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[20]  J. Piette,et al.  Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome , 2019, The Journal of Rheumatology.

[21]  P. Dieudé,et al.  Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? , 2019, Rheumatology.

[22]  X. Mariette,et al.  Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. , 2019, Rheumatology.

[23]  T. Dörner,et al.  Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity , 2019, Annals of the rheumatic diseases.

[24]  K. Neumann,et al.  Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases – A systematic review , 2019, Medicina oral, patologia oral y cirugia bucal.

[25]  X. Mariette,et al.  Rituximab‐Bendamustine (R‐Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS) , 2019, British journal of haematology.

[26]  L. Monassier,et al.  Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options , 2019, Drugs.

[27]  E. Vicaut,et al.  Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. , 2019, Autoimmunity reviews.

[28]  J. Buyon,et al.  Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus , 2018, Annals of the rheumatic diseases.

[29]  T. Paravar.  Less common rheumatologic disorders: Current concepts of skin and systemic manifestations. , 2018, Clinics in dermatology.

[30]  T. Paula,et al.  Lipschütz Genital Ulceration as Initial Manifestation of Primary Sjögren's Syndrome , 2018, Case reports in obstetrics and gynecology.

[31]  G. L. La Paglia,et al.  Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. , 2018, Clinical and experimental rheumatology.

[32]  P. Arriaga,et al.  Dental implants in Sjögren’s syndrome patients: A systematic review , 2017, PloS one.

[33]  A. Baer,et al.  Neurological Complications of Sjögren’s Syndrome: Diagnosis and Management , 2017, Current Treatment Options in Rheumatology.

[34]  L. Lowe,et al.  Cutaneous purpura of Sjögren syndrome successfully treated with hydroxychloroquine , 2017, JAAD case reports.

[35]  R. Moots,et al.  Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome , 2017, Arthritis & rheumatology.

[36]  S. Boisramé,et al.  Conduite à tenir devant une sécheresse buccale , 2017 .

[37]  V. Meas-Yedid,et al.  A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome , 2016, Rheumatology.

[38]  T. Maisonobe,et al.  Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy) , 2016, Medicine.

[39]  J. Garrigue,et al.  Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial , 2016, European journal of ophthalmology.

[40]  Sueko M Ng,et al.  Over the counter (OTC) artificial tear drops for dry eye syndrome. , 2016, The Cochrane database of systematic reviews.

[41]  C. Traversi,et al.  Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in Sjogren's syndrome patients , 2015, Microscopy research and technique.

[42]  R. Priori,et al.  Quality of Sexual Life in Women with Primary Sjögren Syndrome , 2015, The Journal of Rheumatology.

[43]  G. Baron,et al.  Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. , 2015, Annals of the rheumatic diseases.

[44]  A. Shahane,et al.  The epidemiology of Sjögren’s syndrome , 2014, Clinical epidemiology.

[45]  P. Ravaud,et al.  Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. , 2014, JAMA.

[46]  M. Irkec,et al.  Diagnosing the severity of dry eye: a clear and practical algorithm , 2014, British Journal of Ophthalmology.

[47]  X. Mariette,et al.  Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area , 2014, Arthritis care & research.

[48]  X. Mariette,et al.  Treatment of Primary Sjgren Syndrome With Rituximab , 2014, Annals of Internal Medicine.

[49]  R. Potvin,et al.  A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjögren's syndrome. , 2013, Investigative ophthalmology & visual science.

[50]  M. Kurose,et al.  The role of corneal afferent neurons in regulating tears under normal and dry eye conditions. , 2013, Experimental eye research.

[51]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[52]  P. Ravaud,et al.  Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry , 2012, Annals of the rheumatic diseases.

[53]  Min Zhang,et al.  Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye , 2012, British Journal of Ophthalmology.

[54]  W. Mathers,et al.  Hypothesis 3 : Systemic Medications May Induce Dry Eye , 2014 .

[55]  Stefano Tamburin,et al.  Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial , 2012, The Lancet Neurology.

[56]  R. Bourkiza,et al.  A Review of the Complications of Lacrimal Occlusion with Punctal and Canalicular Plugs , 2012, Orbit.

[57]  Sanjay V. Patel,et al.  Scleral lenses in the management of ocular surface disease. , 2014, Ophthalmology.

[58]  Satoru Yamagami,et al.  Tear meniscus evaluation by anterior segment swept-source optical coherence tomography. , 2012, American journal of ophthalmology.

[59]  A. Gabrielli,et al.  A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.

[60]  J. Pers,et al.  Treatment of primary Sjögren syndrome , 2012, Nature Reviews Rheumatology.

[61]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[62]  C. Benhamou,et al.  Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study , 2011, Arthritis care & research.

[63]  F. Paul,et al.  Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders , 2011, Multiple sclerosis.

[64]  L. Misery,et al.  Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjögren's syndrome. , 2010, Journal of autoimmunity.

[65]  J. Stone,et al.  Treatment of primary Sjögren syndrome: a systematic review. , 2010, JAMA.

[66]  A. Vissink,et al.  Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[67]  R. Chalmers,et al.  Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. , 2010, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[68]  C. Shiboski,et al.  A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. , 2010, American journal of ophthalmology.

[69]  Z. Amoura,et al.  Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. , 2009, Arthritis and rheumatism.

[70]  Ying-Ting Chen,et al.  Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye , 2009, Molecular vision.

[71]  P. Emery,et al.  Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study , 2008, Annals of the rheumatic diseases.

[72]  R. Jonsson,et al.  Exocrine function in primary Sjögren syndrome: natural course and prognostic factors , 2007, Annals of the rheumatic diseases.

[73]  C. Roberts,et al.  Comparison of Topical Cyclosporine, Punctal Occlusion, and a Combination for the Treatment of Dry Eye , 2007, Cornea.

[74]  R. Fox,et al.  Sjögren's syndrome in dermatology. , 2006, Clinics in dermatology.

[75]  R. Frydman,et al.  [Sjögren syndrome in Obstetric and Gynecology: literature review]. , 2006, Journal de gynecologie, obstetrique et biologie de la reproduction.

[76]  L. Misery,et al.  Primary Gougerot–Sjögren syndrome: a dermatological approach , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[77]  L. Irgens,et al.  Pregnancy outcome in patients with primary Sjögren's syndrome. a case-control study. , 2005, The Journal of rheumatology.

[78]  H. Diener,et al.  Pulse—cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren's syndrome , 2005, Clinical Neurology and Neurosurgery.

[79]  J. Smallhorn,et al.  Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease , 2004, Circulation.

[80]  S. Vitale,et al.  Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye , 2004, Health and quality of life outcomes.

[81]  Karla Zadnik,et al.  The Repeatability of Clinical Measurements of Dry Eye , 2004, Cornea.

[82]  A. Bron,et al.  Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests , 2003, Cornea.

[83]  George W Ousler,et al.  Alternative reference values for tear film break up time in normal and dry eye populations. , 2000, Advances in experimental medicine and biology.

[84]  R. Schiffman,et al.  Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.

[85]  A. Lambiase,et al.  Topical treatment with nerve growth factor for corneal neurotrophic ulcers. , 1998, The New England journal of medicine.

[86]  T. Maggino,et al.  Gynaecological aspects of primary Sjogren's syndrome. , 1995, European journal of obstetrics, gynecology, and reproductive biology.

[87]  H. Moutsopoulos,et al.  Obstetric and gynaecological profile in patients with primary Sjögren's syndrome. , 1994, Annals of the rheumatic diseases.

[88]  P. Kind,et al.  Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine , 1992, The British journal of dermatology.

[89]  S. Tseng,et al.  Comparison of fluorescein and rose bengal staining. , 1992, Ophthalmology.

[90]  O. P. Bijsterveld,et al.  Diagnostic Tests in the Sicca Syndrome , 1969 .

[91]  M. Harma,et al.  Are the women with Sjögren's Syndrome satisfied with their sexual activity? , 2016, Revista brasileira de reumatologia.

[92]  H. Worthington,et al.  Interventions for the management of dry mouth: non-pharmacological interventions. , 2013, The Cochrane database of systematic reviews.

[93]  R. Dana,et al.  Development and validation of a short global dry eye symptom index. , 2007, The ocular surface.